H.C. Wainwright analyst Arthur He lowered the firm’s price target on Calliditas Therapeutics to $50 from $60 and keeps a Buy rating on the shares post the Q2 report. During the earnings call, management cited market access friction as the main reason for the slower than expected sales growth of Nefecon, marketed as Tarpeyo in the U.S., the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CALT:
- Calliditas Therapeutics price target lowered to $18 from $21 at Guggenheim
- Calliditas Therapeutics announces FDA acceptance of Tarpeyo sNDA
- Calliditas Therapeutics’ NefIgArd phase 3 trial results published in The Lancet
- Calliditas Therapeutics reports publication of NefIgArd Study data in The Lancet
- CALT Earnings this Week: How Will it Perform?
